Login to Your Account

Biopharm America

From biology to platforms to drugs: Astellas approach limiting, but in useful ways

By Randy Osborne
Staff Writer

Wednesday, October 4, 2017

BOSTON – At last week's Biopharm America meeting, Astellas Pharma Inc.'s Salim Mujais sat down with BioWorld Asia for a high-level look at the Tokyo-based firm's efforts in therapeutic areas outside of cancer.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription